T1	Participants 58 125	patients with relapsing-remitting multiple sclerosis: a multicentre
T2	Participants 277 329	patients with relapsing-remitting multiple sclerosis
T3	Participants 562 613	The study was done in 51 centres in nine countries.
T4	Participants 614 752	Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI.
T5	Participants 753 815	Of 720 patients screened, 306 eligible patients were enrolled.
T6	Participants 816 842	Patients, aged 18-50 years
T7	Participants 2101 2156	In patients with relapsing-remitting multiple sclerosis
